Related references
Note: Only part of the references are listed.PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter
Csilla Hegedues et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells
Vicky Goler-Baron et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State
Isabel Garcia-Cao et al.
CELL (2012)
Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies
Laleh Amiri-Kordestani et al.
DRUG RESISTANCE UPDATES (2012)
Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells
Kenneth K. W. To et al.
MOLECULAR CARCINOGENESIS (2012)
Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells
Zhiyong Cheng et al.
LEUKEMIA & LYMPHOMA (2012)
Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine
Karthika Natarajan et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2011)
The ABCG family of membrane-associated transporters: you don't have to be big to be mighty
Ian D. Kerr et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Bid as a potential target of apoptotic effects exerted by low doses of PPARγ and RXR ligands in breast cancer cells
Daniela Bonofiglio et al.
CELL CYCLE (2011)
The controversial role of ABC transporters in clinical oncology
Akina Tamaki et al.
ESSAYS IN BIOCHEMISTRY: ABC TRANSPORTERS (2011)
Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia
Patrick K. Campbell et al.
LEUKEMIA RESEARCH (2011)
ABCG2/BCRP DYSFUNCTION AS A MAJOR CAUSE OF GOUT
Hirotaka Matsuo et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2011)
Mutational Analysis of Threonine 402 Adjacent to the GXXXG Dimerization Motif in Transmembrane Segment 1 of ABCG2
Orsolya Polgar et al.
BIOCHEMISTRY (2010)
Interaction of Angiotensin Receptor Type 1 Blockers with ATP-binding Cassette Transporters
J. Weiss et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2010)
Design and Syntheses of Permethyl Ningalin B Analogues: Potent Multidrug Resistance (MDR) Reversal Agents of Cancer Cells
Pu Yong Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes
Emi Kamiyama et al.
LIFE SCIENCES (2010)
PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells
Anne-Marie Bleau et al.
CELL STEM CELL (2009)
Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling
Chen Hu et al.
CARCINOGENESIS (2008)
Tenets of PTEN tumor suppression
Leonardo Salmena et al.
CELL (2008)
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises
Timothy A. Yap et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Pleiotropic effects of telmisartan:: still more to come?
Ralf A. Benndorf et al.
JOURNAL OF HYPERTENSION (2008)
Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells
Kenneth K. W. To et al.
MOLECULAR CANCER RESEARCH (2008)
Expression of mouse Abcg2 mRNA during hematopoiesis is regulated by alternative use of multiple leader Exons and promoters
Yang Zong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Peroxisome proliferator-activated receptor γ-regulated ABCG2 expression confers cytoprotection to human dendritic cells
Istvan Szatmari et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone
RE Teresi et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Effect of rifampicin on the pharmacokinetics of pioglitazone
T Jaakkola et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Therapeutic roles of peroxisome proliferator-activated receptor agonists
B Staels et al.
DIABETES (2005)
Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells
T Takada et al.
DRUG METABOLISM AND DISPOSITION (2005)
Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface
C Özvegy-Laczka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Pheophorbide a is a specific probe for ABCG2 function and inhibition
RW Robey et al.
CANCER RESEARCH (2004)
Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium
S Aust et al.
LABORATORY INVESTIGATION (2004)
Mutational analysis of ABCG2: Role of the GXXXG motif
O Polgar et al.
BIOCHEMISTRY (2004)
siRNA Selection Server: an automated siRNA oligonucleotide prediction server
BB Yuan et al.
NUCLEIC ACIDS RESEARCH (2004)
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-α activity
M Schupp et al.
CIRCULATION (2004)
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity
SC Benson et al.
HYPERTENSION (2004)
Akt signaling regulates side population cell phenotype via Bcrp1 translocation
M Mogi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites
B Schmidt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy
F Chang et al.
LEUKEMIA (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
ABC transporters as phenotypic markers and functional regulators of stem cells
KD Bunting
STEM CELLS (2002)
PPARγ agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells
S Kitamura et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype
S Zhou et al.
NATURE MEDICINE (2001)
Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN
L Patel et al.
CURRENT BIOLOGY (2001)
Share Paper
